Trial · NCT01318135
Outcomes31
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 20 of 31
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Number of Participants With Adverse Events. | 52 Weeks. | Full Analysis Set was defined as the population of participants randomized in the core phase 2/3 SYR-322/CCT-005 (NCT01318083) or SYR-322/CCT-006 (NCT01318109) add-on studies and received at least 1 dose of the investigational products (SYR-322DB in combination with glimepiride or metformin) for the treatment period were identified for analysis. | participants | NUMBER |
| SECONDARY | Change From Baseline in Glycosylated Hemoglobin (Week 8). | Baseline and Week 8. | Values are from the Full Analysis Set. | percentage of Glycosylated Hemoglobin | MEAN |
| SECONDARY | Change From Baseline in Glycosylated Hemoglobin (Week 12). | Baseline and Week 12. | Values are from the Full Analysis Set. | percentage of Glycosylated Hemoglobin | MEAN |
| SECONDARY | Change From Baseline in Glycosylated Hemoglobin (Week 16). | Baseline and Week 16. | Values are from the Full Analysis Set. | percentage of Glycosylated Hemoglobin | MEAN |
| SECONDARY | Change From Baseline in Glycosylated Hemoglobin (Week 20). | Baseline and Week 20. | Values are from the Full Analysis Set. | percentage of Glycosylated Hemoglobin | MEAN |
| SECONDARY | Change From Baseline in Glycosylated Hemoglobin (Week 24). | Baseline and Week 24. | Values are from the Full Analysis Set. | percentage of Glycosylated Hemoglobin | MEAN |
| SECONDARY | Change From Baseline in Glycosylated Hemoglobin (Week 28). | Baseline and Week 28. | Values are from the Full Analysis Set. | percentage of Glycosylated Hemoglobin | MEAN |
| SECONDARY | Change From Baseline in Glycosylated Hemoglobin (Week 32). | Baseline and Week 32. | Values are from the Full Analysis Set. | percentage of Glycosylated Hemoglobin | MEAN |
| SECONDARY | Change From Baseline in Glycosylated Hemoglobin (Week 36). | Baseline and Week 36. | Values are from the Full Analysis Set. | percentage of Glycosylated Hemoglobin | MEAN |
| SECONDARY | Change From Baseline in Glycosylated Hemoglobin (Week 40). | Baseline and Week 40. | Values are from the Full Analysis Set. | percentage of Glycosylated Hemoglobin | MEAN |
| SECONDARY | Change From Baseline in Glycosylated Hemoglobin (Week 44). | Baseline and Week 44. | Values are from the Full Analysis Set. | percentage of Glycosylated Hemoglobin | MEAN |
| SECONDARY | Change From Baseline in Glycosylated Hemoglobin (Week 48). | Baseline and Week 48. | Values are from the Full Analysis Set. | percentage of Glycosylated Hemoglobin | MEAN |
| SECONDARY | Change From Baseline in Glycosylated Hemoglobin (Week 52). | Baseline and Week 52. | Values are from the Full Analysis Set. | percentage of Glycosylated Hemoglobin | MEAN |
| SECONDARY | Change From Baseline in Glycosylated Hemoglobin (Final Visit). | Baseline and Final Visit (up to 52). | Values are from the Full Analysis Set. | percentage of Glycosylated Hemoglobin | MEAN |
| SECONDARY | Change From Baseline in Fasting Blood Glucose (Week 8). | Baseline and Week 8. | Values are from the Full Analysis Set. | mg/dL | MEAN |
| SECONDARY | Change From Baseline in Fasting Blood Glucose (Week 12). | Baseline and Week 12. | Values are from the Full Analysis Set. | mg/dL | MEAN |
| SECONDARY | Change From Baseline in Fasting Blood Glucose (Week 16). | Baseline and Week 16. | Values are from the Full Analysis Set. | mg/dL | MEAN |
| SECONDARY | Change From Baseline in Fasting Blood Glucose (Week 20). | Baseline and Week 20. | Values are from the Full Analysis Set. | mg/dL | MEAN |
| SECONDARY | Change From Baseline in Fasting Blood Glucose (Week 24). | Baseline and Week 24. | Values are from the Full Analysis Set. | mg/dL | MEAN |
| SECONDARY | Change From Baseline in Fasting Blood Glucose (Week 28). | Baseline and Week 28. | Values are from the Full Analysis Set. | mg/dL | MEAN |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01318135/outcomes